Pascal Soriot, AstraZeneca CEO (David Zorrakino/Europa Press via AP)

FDA ap­proves As­traZeneca's Lyn­parza com­bo for adults with BR­CA-mu­tat­ed prostate can­cer

In April, an FDA ad­comm gave the thumbs up to As­traZeneca’s block­buster PARP in­hibitor Lyn­parza la­bel ex­pan­sion in­to prostate can­cer — but on­ly for pa­tients whose tu­mors have a BR­CA mu­ta­tion.

On Wednes­day, the FDA fol­lowed the ad­comm’s rec­om­men­da­tion and ap­proved Lyn­parza in com­bi­na­tion with abi­raterone (Zyti­ga) and pred­nisone or pred­nisolone for adult pa­tients with BR­CA-mu­tat­ed metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer (mCR­PC).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.